Hematology Frontier

The widespread adoption of targeted therapies has significantly improved long-term outcomes for patients with chronic lymphocytic leukemia (CLL). However, a critical question has remained unanswered: Is fixed-duration therapy as effective as continuous treatment? Until now, no prospective head-to-head evidence had directly compared these two strategies.

The 2025 Annual Meeting of the American Society of Hematology (ASH 2025) has recently concluded in Orlando, USA. As the “year-end flagship event” in hematology, this year’s meeting presented a…

In this video from ASH, Prof. Wojciech Jurczak, consultant hematologist and Head of Department at the Maria Skłodowska-Curie National Research Institute of Oncology, shares key results from the randomized…

In this video, Prof. Othman Al-Sawaf, hematologist and clinical investigator at the University Hospital Cologne and the German CLL Study Group, shares key findings from a randomized study comparing fixed-duration…

From December 6 to 9, 2025, the 67th Annual Meeting of the American Society of Hematology (ASH) was held in Orlando, USA. As the largest and most influential international conference…

Multiple myeloma (MM) is a malignant hematologic tumor originating from plasma cells. Despite significant advances in available therapies, disease relapse and drug resistance remain major barriers to achieving a cure.…

Organized by Institute of Hematology & Blood Disease Hospital, Chinese Academy of Medical Sciences, the 6th Annual Meeting of Chinese Alliance for Society of Hematology (CASH) will be held on Jan. 9-11, 2026, in Tianjin, China. Since its inaugural session in 2021, CASH has become one of the most influential academic events in the field of hematology. Looking back at the previous five sessions, the conference has invited top experts and scholars from both China and abroad, attracting millions of online and onsite participants. It has focused on national strategies, exchanged the latest research findings, discussed trends in the development of the discipline, and helped integrate Chinese hematology with the international community, playing an irreplaceable role in the implementation of the Healthy China strategy.

Immune thrombocytopenia (ITP) is an acquired autoimmune disorder, and management after failure of first-line corticosteroid therapy remains a significant clinical challenge. In recent years, emerging therapies targeting key pathways involved…

Diffuse large B-cell lymphoma (DLBCL) is a common and aggressive form of lymphoma, but its management is particularly challenging in elderly patients. Standard R-CHOP chemotherapy is often poorly tolerated in…

In recent years, the field of hematologic malignancies has advanced at an unprecedented pace, with a steady emergence of novel therapies. While prolonging survival remains a central goal, patients’ quality…